Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denagliptin in Type 2 Diabetes Mellitus (Randomized, Double-Blind, Placebo-Controlled, Phase 2)
2006-002157-79Phase 2Terminated
- Sponsor
- GSK
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Denagliptin with Placebo (2 arms). Primary endpoints: Primary efficacy endpoint and Primary safety and tolerability endpoint. Started Jul 2006; status: terminated.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-002157-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002157-79.